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Introduction
The genetics and pathogenesis of splenic marginal zone
lymphoma (SMZL) are poorly understood. The lymphoma
lacks recurrent chromosome translocation, a common feature
in other low grade B-cell lymphomas. Approximately 30% of
cases have 7q deletion, but the gene targeted by the deletion
is unknown. Although 7q deletion is a characteristic feature
of SMZL, clinicopathological investigation and gene expres-
sion microarray analyses to date show that the cases with 7q
deletion do not constitute a distinct subgroup. Thus, it is like-
ly that there is a common molecular mechanism between
SMZL with and without 7q deletion. 
A recent study showed inactivating mutation of A20, also
known as TNFAIP3, in 1 of 12 (8%) SMZLs.1 A20 encodes for
a “global” NF-kB negative regulator and is frequently inacti-
vated by mutation/deletion in several B-cell lymphomas char-
acterized by constitutive NF-kB activation including MALT
lymphoma, activated B-cell like diffuse large B-cell lym-
phoma (ABC-DLBCL), Hodgkin’s lymphoma and primary
mediastinal large B-cell lymphoma.1-7 In addition to A20, sev-
eral NF-kB positive regulators, including CARD11, MYD88
and CD79 are frequently activated by mutation in ABC-
DLBCL.8-10 Our recent study also showed frequent inactiva-
tion of ABIN1, a critical adaptor molecule of the A20 inhibito-
ry complex, in gastrointestinal DLBCL.7 In the light of these
findings and the biological connection of these NF-κB regula-
tors, we investigated whether they are also targeted by genet-
ic changes in SMZL. 
Design amd Methods
Patients’ materials
A total of 57 cases of well-characterized SMZL were investigated in
the present study. The diagnosis of these lymphomas was made
based on histological assessment of the spleen according to the latest
WHO classification of tumors of hematopoietic and lymphoid tis-
sues.11 The DNA samples extracted from the lymphoma involved
spleen were available from a previous study and these included 23
cases from frozen tissues and 34 cases from formalin fixed paraffin
embedded tissues.12 Due to a lack of sufficient DNA for some sam-
ples, mutation screening could not be comprehensively performed for
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The genetics and pathogenesis of splenic marginal zone lym-
phoma are poorly understood. The lymphoma lacks chromo-
some translocation, and approximately 30% of cases are fea-
tured by 7q deletion, but the gene targeted by the deletion is
unknown. A recent study showed inactivation of A20, a “glob-
al” NF-kB negative regulator, in 1 of 12 splenic marginal zone
lymphomas. To investigate further whether deregulation of the
NF-kB pathway plays a role in the pathogenesis of splenic mar-
ginal zone lymphoma, we screened several NF-kB regulators
for genetic changes by PCR and sequencing. Somatic muta-
tions were found in A20 (6/46=13%), MYD88 (6/46=13%),
CARD11 (3/34=8.8%), but not in CD79A, CD79B and ABIN1.
Interestingly, these genetic changes are largely mutually exclu-
sive from each other and MYD88 mutation was also mutually
exclusive from 7q deletion. These results strongly suggest that
deregulation of the TLR (toll like receptor) and BCR (B-cell
receptor) signaling pathway may play an important role in the
pathogenesis of splenic marginal zone lymphoma.
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ABSTRACT
each case. Genetic data on 7q deletion, TP53 mutation and IGH
mutation were available from a previous study.12 Local ethical
guidelines were followed for the use of archival tissues for
research with the approval of the ethics committees of the institu-
tions involved.
PCR and DNA sequencing
CARD11, CD79A, CD79B, MYD88, A20 and ABIN1were inves-
tigated for mutation by PCR and DNA sequencing. For MYD88,
A20 and ABIN1, all coding exons were studied. For CARD11,
exons 5-9, which encode the coiled-coil domain, were investigated
as mutation was exclusively found in this region,8 while for
CD79A and CD79B, only coding exons (5 and 6) containing the
mutation hot spots were examined. The primer sequences and
PCR conditions are shown in the Online Supplementary Table S1.
PCR products were routinely purified and sequenced from both
orientations using the BigDye terminator chemistry 3.1 system
(Applied Biosystems, Foster City, CA, USA). In each case, muta-
tion was confirmed by at least two independent PCR and sequenc-
ing experiments. The somatic mutation was excluded from poly-
morphisms and germline mutation by database search and analy-
sis of the DNA samples extracted from the microdissected normal
cells as described previously.7
In cases where double mutations were found in the same gene,
we also investigated whether the double mutations affected one
or both alleles. The region spanning the double mutations was
amplified and the PCR product was cloned using the TOPO TA
Cloning Kit (Invitrogen, Paisley, UK). The plasmid DNA was
extracted from multiple clones using the QIAprep Spin Miniprep
Kit (QIAGEN, Crawley, UK) and then sequenced using the BigDye
terminator chemistry 3.1 with vector primers.
Statistical analysis
Correlation among categorical variables was evaluated by
Fisher’s exact probability test. Probabilities of overall survival and
event free survival were calculated by the Kaplan-Meier method
and the comparison between subgroups was carried out by using
the log rank test. P values <0.05 were considered statistically sig-
nificant.  
Results and Discussion
A total of 4 CARD11 mutations were identified in 3
(8.8%) of the 34 SMZLs investigated, with a single case
(C18) harboring two genetic alterations, one missense
mutation and one in-frame deletion in exon 5 (Figure 1 and
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Figure 1. CARD11, MYD88 and A20 mutations and their distribution.  
Online Supplementary Table S1). All 4 mutations were novel.
Among the 3 cases with CARD11mutation, sufficient nor-
mal cells could be microdissected for DNA preparation
only in case C18 and analysis of the normal DNA extracted
confirmed the somatic origin of the double mutation
(Online Supplementary Figure S1). To further investigate
whether the two mutations occurred on the same allele,
we cloned and sequenced the PCR product and the results
showed that the two mutations affected the same allele.
Although the functional impact of the novel CARD11
mutations reported here is unknown, all the 20 CARD11
mutants, including an in-frame deletion which has been
investigated in previous studies, show gain of function,
being more potent in NF-kB activation than the wild type
as demonstrated by in vitro reporter assay.7-8
MYD88 mutation was seen in 6 (13%) of the 46 SMZLs
investigated and in each of these cases, the mutation was a
recurrent missense change (L265P) in the TIR domain,
which was the most frequent alteration in DLBCL (Figure
1 and Online Supplementary Table S2).9 In the 2 cases with
the MYD88 mutation, DNA was successfully extracted
from microdissected normal cells and analyses of the nor-
mal DNA confirmed the somatic origin of the mutation.
The function of the MYD88 L265P mutation has been
investigated and the mutant promotes cell survival by
enhancing the NF-kB and JAK-STAT3 signaling.9
A total of 6 A20 mutations were seen in 6 (13%) of the
46 cases investigated and all of them were potentially func-
tionally disruptive changes including 4 out-frame deletion /
insertion and 2 nonsense mutations (Figure 1 and Online
Supplementary Table S2). In 3 cases with A20 mutation,
DNA was successfully extracted from microdissected nor-
mal cells and analyses of the normal DNA confirmed the
somatic origin of the mutation. The nature and distribution
of the A20 mutations seen in the present study were simi-
lar to those reported previously.1,3-7 These mutations most
likely inactivate the NF-kB inhibitory function of A20.
PCR and sequencing of all the coding exons of ABIN1
showed no evidence of mutation in 34 cases of SMZL.
Similarly, analyses of CD79A exon 5 and CD79B exons 5
and 6, in which mutation hotspots were seen in DLBCL,10
did not demonstrate any mutation in 34 cases of SMZL
investigated.
Of the 57 cases investigated, 31 had complete data on
CARD11, MYD88, A20 and TP53 mutation as well as 7q
deletion, thus allowing comprehensive correlation analy-
ses. Interestingly, CARD11, MYD88 and A20 mutations
were largely mutually exclusive with only a single case
showing concurrent CARD11 and MYD88 mutation
(Figure 2). These mutations were also largely mutually
exclusive from the TP53 mutations (Figure 2). In addition,
MYD88mutation was mutually exclusive from 7q deletion
(P=0.065), while A20mutation was often detected in cases
with 7q deletion (P=0.068). There was no association
between CARD11, MYD88 and A20 mutations, and IGH
hyper-somatic mutation. Overall, 38% of SMZLs investi-
gated showed somatic mutations in either CARD11,
MYD88 or A20 genes. None of the above genetic abnor-
malities correlated with overall or event free survival
(Online Supplementary Table S3).
During the writing of this manuscript, Rossi and col-
leagues also reported frequent but mutually exclusive
genetic abnormalities in multiple NF-kB regulators
involved in both the canonical (A20 and IKBkB) and non-
canonical (BIRC3, TRAF3, MAP3K14) activation path-
ways.13 Of note, both the present study and that by Rossi
and colleagues reported an identical incidence of A20
somatic mutation in SMZL, but Rossi and colleagues found
no evidence of CARD11 and MYD88 somatic mutation in
their pilot screening of a discovery panel of 18 SMZL.
Conventional PCR and Sanger sequencing were used in
both studies, and the reason underlying the discrepancies
in the CARD11 and MYD88 mutation between the two
studies is  not clear.  
CARD11 is a scaffolding molecule that links the BCR sig-
naling to the canonical NF-kB activation pathway (Online
Supplementary Figure S2). IKBkB encodes IKKβ, a critical
component of the IKK complex that is responsible for the
phosphorylation and subsequent degradation of IKB, thus
activation of the canonical NF-kB pathway. MYD88 is a
universal adaptor for IL1-R and TLRs with the exception of
TLR3, and also couples the receptor signaling to the canon-
ical NF-kB, AP1 and IRF activation pathway (Online
Supplementary Figure S2). A20, a ubiquitin modification
enzyme, can specifically remove the K63-linked ubiquitin
chain that is crucial for protein function, and catalyses the
K48-linked polyubiquitination that targets proteins for pro-
teasome degradation.14-15 Through such ubiquitin modifica-
tion, A20 inactivates several proteins including RIP-1,
TRAF6, NEMO and TAK1, and thus negatively regulates
the TLR/IL1-R and BCR signaling (Online Supplementary
Figure S2).16-18 MAP3K14 encodes NIK, an essential positive
regulator of the non-canonical NF-κB activation pathway.
NIK is negatively regulated by TRAF3 and BIRC3 (also
known as API2). The finding of somatic mutation in the
above diverse regulators involving multiple cellular signal-
ing pathways, particularly the BCR and TLR signaling,
strongly suggests that a constitutive activation of these
pathways may play an important role in the pathogenesis
of SMZL. 
The above hypothesis is also supported by several
strands of evidence from previous studies, which also indi-
cate a role for chronic antigenic stimulation in the develop-
ment of SMZL. Firstly, around 12% of SMZL have a stereo-
typed IGH CDR3,19 strongly suggesting the importance of
antigen receptor signaling in the lymphoma development.
Secondly, at least in Italy, 19% of SMZL are associated
with HCV infection and a high proportion of these lym-
CARD11, MYD88 and A20 mutation in SMZL 
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Figure 2. Correlation between 7q deletion, TP53, CARD11, MYD88
and A20 mutation. 
phomas respond to antiviral treatment alone.20
Nonetheless, the nature and molecular mechanisms of the
implicated antigenic stimulation in SMZL have yet to be
clarified. Identification of such antigenic stimuli and com-
prehensive investigation of genetic abnormalities in the
NF-kB pathway will unravel the molecular pathogenesis of
SMZL and provide critical insights into a strategy for tar-
geted therapy.
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
Q. yan et al.
598 haematologica | 2012; 97(4)
References
1. Novak U, Rinaldi A, Kwee I, Nandula SV,
Rancoita PM, Compagno M, et al. The NF-
{kappa}B negative regulator TNFAIP3 (A20)
is inactivated by somatic mutations and
genomic deletions in marginal zone lym-
phomas. Blood. 2009;113(20):4918-21.
2. Chanudet E, Huang Y, Ichimura K, Dong G,
Hamoudi RA, Radford J, et al. A20 is target-
ed by promoter methylation, deletion and
inactivating mutation in MALT lymphoma.
Leukemia. 2010;24(2):483-7.
3. Kato M, Sanada M, Kato I, Sato Y, Takita J,
Takeuchi K, et al. Frequent inactivation of
A20 in B-cell lymphomas. Nature. 2009;
459(7247):712-6.
4. Compagno M, Lim WK, Grunn A, Nandula
SV, Brahmachary M, Shen Q, et al.
Mutations of multiple genes cause deregula-
tion of NF-kappaB in diffuse large B-cell
lymphoma. Nature. 2009;459(7247):717-21.
5. Schmitz R, Hansmann ML, Bohle V, Martin-
Subero JI, Hartmann S, Mechtersheimer G,
et al. TNFAIP3 (A20) is a tumor suppressor
gene in Hodgkin lymphoma and primary
mediastinal B cell lymphoma. J Exp Med.
2009;206(5):981-9.
6. Honma K, Tsuzuki S, Nakagawa M, Tagawa
H, Nakamura S, Morishima Y, et al.
TNFAIP3/A20 functions as a novel tumor
suppressor gene in several subtypes of non-
Hodgkin lymphomas. Blood. 2009;114(12):
2467-75.
7. Dong G, Chanudet E, Zeng N, Appert A,
Chen YW, Au WY, et al. A20, ABIN-1/2, and
CARD11 mutations and their prognostic
value in gastrointestinal diffuse large B-cell
lymphoma. Clin Cancer Res. 2011;17(6):
1440-51.
8. Lenz G, Davis RE, Ngo VN, Lam L, George
TC, Wright GW, et al. Oncogenic CARD11
mutations in human diffuse large B cell lym-
phoma. Science. 2008;319(5870):1676-9.
9. Ngo VN, Young RM, Schmitz R, Jhavar S,
Xiao W, Lim KH, et al. Oncogenically active
MYD88 mutations in human lymphoma.
Nature. 2011;470(7332):115-9.
10. Davis RE, Ngo VN, Lenz G, Tolar P, Young
RM, Romesser PB, et al. Chronic active B-
cell-receptor signalling in diffuse large B-cell
lymphoma. Nature. 2010;463(7277):88-92.
11. Isaacson PG, Piris MA, Berger F, Swerdlow
SH, Thieblemont C, Pittaluga S, et al.
“Splenic B-Cell Marginal Zone Lymphoma,”
in WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues,
(Lyon: International Agency for Research on
Cancer, 2007), pp. 185-7.
12. Watkins AJ, Huang Y, Ye H, Chanudet E,
Johnson N, Hamoudi R, et al. Splenic mar-
ginal zone lymphoma: characterization of
7q deletion and its value in diagnosis. J
Pathol. 2010;220(4):461-74.
13. Rossi D, Deaglio S, Dominguez-Sola D, Rasi
S, Vaisitti T, Agostinelli C, et al. Alteration of
BIRC3 and multiple other NF-kB pathway
genes in splenic marginal zone lymphoma.
Blood. 2011;118(18):4930-4. 
14. Sun SC. Deubiquitylation and regulation of
the immune response. Nat Rev Immunol.
2008;8(7):501-11.
15. Coornaert B, Carpentier I, Beyaert R. A20:
central gatekeeper in inflammation and
immunity. J Biol Chem. 2009;284(13): 8217-
21.
16. Vereecke L, Beyaert R, Van Loo G. The ubiq-
uitin-editing enzyme A20 (TNFAIP3) is a
central regulator of immunopathology.
Trends Immunol. 2009;30(8):383-91.
17. Boone DL, Turer EE, Lee EG, Ahmad RC,
Wheeler MT, Tsui C, et al. The ubiquitin-
modifying enzyme A20 is required for ter-
mination of Toll-like receptor responses. Nat
Immunol. 2004;5(10):1052-60.
18. Thome M, Tschopp J. TCR-induced NF-
kappaB activation: a crucial role for Carma1,
Bcl10 and MALT1. Trends Immunol.
2003;24(8):419-24.
19. Zibellini S, Capello D, Forconi F, Marcatili P,
Rossi D, Rattotti S, et al. Stereotyped pat-
terns of B-cell receptor in splenic marginal
zone lymphoma. Haematologica. 2010;95
(10):1792-6.
20. Arcaini L, Bruno R. Hepatitis C virus infec-
tion and antiviral treatment in marginal zone
lymphomas. Curr Clin Pharmacol. 2010;5
(2):74-81.
